Trial Profile
A Phase I/IIa, Open Label, Dose-escalating Clinical Study to Evaluate the Safety, Tolerability and Theraputic Effects of Transplantation of Astrocytes Derived From Human Embryonic Stem Cells (hESC), in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jan 2021
Price :
$35
*
At a glance
- Drugs Astrocyte cell therapy Kadimastem (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions; First in man
- Sponsors Kadimastem
- 14 Jan 2021 Status changed from recruiting to completed.
- 15 Dec 2020 Results from cohort B of the study presented in a Kadimastem media release.
- 03 Aug 2020 According to a Kadimastem media release, the final results of the 6-month follow-up post-treatment for Cohort B are expected in Q4 2020.